Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-05

AUTHORS

Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon

ABSTRACT

The bcr–abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein. Cellular proliferation and tumor formation by Bcr–Abl–expressing cells were specifically inhibited by this compound. In colony–forming assays of peripheral blood or bone marrow from patients with CML, there was a 92–98% decrease in the number of bcr–abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr–abl–positive leukemias. More... »

PAGES

561-566

Journal

TITLE

Nature Medicine

ISSUE

5

VOLUME

2

Related Patents

  • Compounds And Methods For The Treatment Of Cancer
  • Design, Synthesis And Evaluation Of Procaspase Activating Compounds As Personalized Anti-Cancer Drugs
  • Compositions And Methods For Treating Leukemia
  • Design, Synthesis And Evaluation Of Procaspase Activating Compounds As Personalized Anti-Cancer Drugs
  • Substituted Quinoxalines And Uses Thereof
  • Episomal Fusion Gene
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Using Erastin As Therapeutic Agent In Treatment Of Cell Proliferative Disorders Associated With Mutation In Ras Gene
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • Uses Of Diazepane Derivatives
  • Male Contraceptive Compositions And Methods Of Use
  • Treatment Of Restenosis And Stenosis With Dasatinib
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Method To Identify Cancer Fusion Genes
  • Therapy For Kinase-Dependent Malignancies
  • Therapeutic Targeting Of Myeloproliferative Neoplasms By Dusp1 Inhibition
  • Male Contraceptive Compositions And Methods Of Use
  • Diazepane Derivatives And Uses Thereof
  • Prodrug Anti-Cancer Therapy
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • 4-Diethylamino-N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-(Trifluoromethyl)-Benzamide; Disease Which Responds To An Inhibition Of Protein Kinase Activity, Especially A Neoplastic Disease; Leukemia
  • Design, Synthesis And Evaluation Of Procaspase Activating Compounds As Personalized Anti-Cancer Drugs
  • Acetamide Thienotriazolodiazepines And Uses Thereof
  • Thienotriazolodiazepine Compounds For Treating Neoplasia
  • Theramutein Modulators
  • Combination Of Pyrimidylaminobenzamide Compounds And Imatinib For Treating Or Preventing Proliferative Diseases
  • Substituted Quinoxalines As Kinase Inhibitors
  • Cyano Thienotriazolodiazepines And Uses Thereof
  • Compounds For Modulating T-Cells
  • Compounds And Methods Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders
  • Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Theramutein Modulators
  • Such As The Abl Tyrosine Kinase Domain; Leukemia
  • Compounds And Methods Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Pyrrolo-Pyridine Kinase Modulators
  • Peptide Inhibitors Of Abl Kinases
  • Peptide Inhibitors Of Bcr-Abl Oligomerization
  • Theramutein Modulators
  • Compositions And Methods Including Cell Death Inducers And Procaspase Activation
  • Diaminopyrimidine Benzenesulfone Derivatives And Uses Thereof
  • Administering A Mixture Of 4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]-N-[5-(4-Methyl-1h-Imidazol-1-Yl)-3-(Trifluoromethyl)Phenyl]Benzamide And 4-(4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide; Combination Therapy; Antitumor Agents
  • Quinoxaline Derivatives As Antitumor Agents
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • Theramutein Modulators
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Zebrafish Animal Models For Clarifying Gene Function Relationships In Hyperproliferative Disorders; Antisense Agents; Rna Interference And Tumor Treatment Therapies
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders
  • Procaspase Activating Compounds
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Nup214-Abl1 Fusion Product, Important In The Development Of T-Cell Acute Lymphoblastic Leukemia; Methods To Detect The Fusion And Prevention Of The Oncogenic Activity Of The Fusion Product
  • Dihydropteridinone Derivatives And Uses Thereof
  • Modulators Of Gtpase And Use In Relevant Treatment
  • Pyrrolo-Pyridine Kinase Modulators
  • Theramutein Modulators
  • Identification Of Genotype-Selective Anti-Tumor Agents
  • Blocking Or Activation Of Endogenous Proteins Variations Rncoded By Mutated Gees
  • Inhibitors Of Transcription Factors And Uses Thereof
  • Determining Polypeptide Sequence Of At Least One Bcr-Abl Polypeptide Expressed By The Human Cancer Cell And Comparing The Polypeptide Sequence Of The Bcr-Abl Polypeptide Expressed By The Human Cancer Cell To The Bcr-Abl Polypeptide Sequence
  • Combination Therapy Of Transcription Inhibitors And Kinase Inhibitors
  • Bivalent Bromodomain Inhibitors And Uses Thereof
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • Diagnostic And Prognostic Assays Based On Circulating Tyrosine Kinase Activity
  • Diagnostic Substance, That Reacts With Molecules Which Appear In A Transformed And/Or Infected Biological Cell; Tumor Disease Or/And An Infectious Disease
  • Compositions And Methods Relating To Fusion Protein Biomarkers
  • Prodrug Anti-Cancer Therapy
  • Erastin And Erastin Binding Proteins, And Uses Thereof
  • Detection Of Gleevec Resistance
  • Diaminopyrimidine Benzenesulfone Derivatives And Uses Thereof
  • Compositions And Methods Including Cell Death Inducers And Procaspase Activation
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To St1-571
  • Detection Of Gleevec Resistant Mutations
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nm0596-561

    DOI

    http://dx.doi.org/10.1038/nm0596-561

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1051513257

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/8616716


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Benzamides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Cells", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bone Marrow", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Evaluation Studies as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fusion Proteins, bcr-abl", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Imatinib Mesylate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Piperazines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins c-abl", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pyrimidines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Stem Cells", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Druker", 
            "givenName": "Brian J.", 
            "id": "sg:person.012015172137.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012015172137.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tamura", 
            "givenName": "Shu", 
            "id": "sg:person.0603442270.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603442270.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Buchdunger", 
            "givenName": "Elisabeth", 
            "id": "sg:person.01060303730.59", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060303730.59"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ohno", 
            "givenName": "Sayuri", 
            "id": "sg:person.0717670670.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717670670.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Segal", 
            "givenName": "Gerald M.", 
            "id": "sg:person.01111173543.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111173543.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fanning", 
            "givenName": "Shane", 
            "id": "sg:person.01123641753.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123641753.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zimmermann", 
            "givenName": "J\u00fcrg", 
            "id": "sg:person.07363226302.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07363226302.25"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lydon", 
            "givenName": "Nicholas B.", 
            "id": "sg:person.01017774522.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017774522.42"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/306277a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004442914", 
              "https://doi.org/10.1038/306277a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/243290a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012018569", 
              "https://doi.org/10.1038/243290a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00124317", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011028642", 
              "https://doi.org/10.1007/bf00124317"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/306239a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007822085", 
              "https://doi.org/10.1038/306239a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/315550a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045340731", 
              "https://doi.org/10.1038/315550a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1982.75", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008842076", 
              "https://doi.org/10.1038/bjc.1982.75"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/376785a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022545215", 
              "https://doi.org/10.1038/376785a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1996-05", 
        "datePublishedReg": "1996-05-01", 
        "description": "The bcr\u2013abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr\u2013Abl fusion protein. Cellular proliferation and tumor formation by Bcr\u2013Abl\u2013expressing cells were specifically inhibited by this compound. In colony\u2013forming assays of peripheral blood or bone marrow from patients with CML, there was a 92\u201398% decrease in the number of bcr\u2013abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr\u2013abl\u2013positive leukemias.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nm0596-561", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2410754", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1113716", 
            "issn": [
              "1078-8956", 
              "1546-170X"
            ], 
            "name": "Nature Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "2"
          }
        ], 
        "keywords": [
          "chronic myelogenous leukemia", 
          "BCR-ABL positive cells", 
          "BCR-ABL fusion protein", 
          "tyrosine kinase", 
          "colony-forming assays", 
          "normal colony formation", 
          "peripheral blood", 
          "BCR-ABL oncogene", 
          "myelogenous leukemia", 
          "positive cells", 
          "bone marrow", 
          "positive leukemia", 
          "BCR-ABL", 
          "tumor formation", 
          "colony formation", 
          "cellular proliferation", 
          "selective inhibitor", 
          "patients", 
          "Abl tyrosine kinase", 
          "leukemia", 
          "Abl protein tyrosine kinase", 
          "cells", 
          "protein tyrosine kinases", 
          "fusion protein", 
          "marrow", 
          "disease", 
          "blood", 
          "kinase", 
          "treatment", 
          "inhibitors", 
          "proliferation", 
          "inhibition", 
          "cause", 
          "oncogene", 
          "assays", 
          "effect", 
          "decrease", 
          "protein", 
          "compounds", 
          "number", 
          "colonies", 
          "formation", 
          "growth"
        ], 
        "name": "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells", 
        "pagination": "561-566", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1051513257"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nm0596-561"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "8616716"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nm0596-561", 
          "https://app.dimensions.ai/details/publication/pub.1051513257"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:51", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_288.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nm0596-561"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'


     

    This table displays all metadata directly associated to this object as RDF triples.

    258 TRIPLES      21 PREDICATES      94 URIs      79 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nm0596-561 schema:about N0e9fb51cc95a4c5a8bff0fb714cb4cd7
    2 N30844e978a1b462e821370876cf57209
    3 N60fe9d1254504a38a7bf9d49322f0614
    4 N72ecbda58de94354b34b44cd17491bd2
    5 N73480eb3f1e94eb89aaa99ee09a736fc
    6 N7b9011032abe4b35bfa5951db386ce07
    7 N7e16d84c13c54e4797bb52621cb92dc0
    8 N8309cd70d53b4f36984a66b01364aa26
    9 N84d9fc1965a14e97870a2631e61c776e
    10 N88640ac7e0f349d7be0dcaa5a515b8d2
    11 N8f32df8936524a35a98ee75be95269ab
    12 Nb9ebbbbcb2d64c9f8a4c884396129930
    13 Nc3a0ba1daaea49338ca4f93d4b5f133c
    14 Nc59d1562b22c43d8a533cd6f199aad65
    15 Ne8113372d890432ca4e1c0f8d2443016
    16 Ned74a98405454ca988fbb098a999a6d1
    17 Nf3dad74e45a5464e8cfbe49d7e534282
    18 Nfb95fecde54b47e4b020c08900ebe365
    19 anzsrc-for:11
    20 anzsrc-for:1102
    21 schema:author N18ecbe6c261c49f7929dc36e424bfac6
    22 schema:citation sg:pub.10.1007/bf00124317
    23 sg:pub.10.1038/243290a0
    24 sg:pub.10.1038/306239a0
    25 sg:pub.10.1038/306277a0
    26 sg:pub.10.1038/315550a0
    27 sg:pub.10.1038/376785a0
    28 sg:pub.10.1038/bjc.1982.75
    29 schema:datePublished 1996-05
    30 schema:datePublishedReg 1996-05-01
    31 schema:description The bcr–abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein. Cellular proliferation and tumor formation by Bcr–Abl–expressing cells were specifically inhibited by this compound. In colony–forming assays of peripheral blood or bone marrow from patients with CML, there was a 92–98% decrease in the number of bcr–abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr–abl–positive leukemias.
    32 schema:genre article
    33 schema:isAccessibleForFree false
    34 schema:isPartOf N4b76988fabb44c4e9a63ce96f711fbec
    35 Nfa343c8274514708af289b0f9c0e15d5
    36 sg:journal.1113716
    37 schema:keywords Abl protein tyrosine kinase
    38 Abl tyrosine kinase
    39 BCR-ABL
    40 BCR-ABL fusion protein
    41 BCR-ABL oncogene
    42 BCR-ABL positive cells
    43 assays
    44 blood
    45 bone marrow
    46 cause
    47 cells
    48 cellular proliferation
    49 chronic myelogenous leukemia
    50 colonies
    51 colony formation
    52 colony-forming assays
    53 compounds
    54 decrease
    55 disease
    56 effect
    57 formation
    58 fusion protein
    59 growth
    60 inhibition
    61 inhibitors
    62 kinase
    63 leukemia
    64 marrow
    65 myelogenous leukemia
    66 normal colony formation
    67 number
    68 oncogene
    69 patients
    70 peripheral blood
    71 positive cells
    72 positive leukemia
    73 proliferation
    74 protein
    75 protein tyrosine kinases
    76 selective inhibitor
    77 treatment
    78 tumor formation
    79 tyrosine kinase
    80 schema:name Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
    81 schema:pagination 561-566
    82 schema:productId N61de02b4e1494c47a897e3a85e3a0137
    83 N6f046c095cca4813864d9b837c298576
    84 Nb9f33614dcdb45399a50b0a1d0bd164e
    85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051513257
    86 https://doi.org/10.1038/nm0596-561
    87 schema:sdDatePublished 2022-08-04T16:51
    88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    89 schema:sdPublisher N40461722296b435f8f29a53a47d5fe99
    90 schema:url https://doi.org/10.1038/nm0596-561
    91 sgo:license sg:explorer/license/
    92 sgo:sdDataset articles
    93 rdf:type schema:ScholarlyArticle
    94 N00dca75c6e504cc895ef955c9df74fc7 rdf:first sg:person.0717670670.09
    95 rdf:rest N85997ee65fc64b46b5720141d8b25609
    96 N0e9fb51cc95a4c5a8bff0fb714cb4cd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Benzamides
    98 rdf:type schema:DefinedTerm
    99 N13f86cdc319440a6b199e1a6f4cfcf43 rdf:first sg:person.01017774522.42
    100 rdf:rest rdf:nil
    101 N18ecbe6c261c49f7929dc36e424bfac6 rdf:first sg:person.012015172137.23
    102 rdf:rest Nfaff3179e4d1441db8898d26b9b173be
    103 N30844e978a1b462e821370876cf57209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    104 schema:name Dose-Response Relationship, Drug
    105 rdf:type schema:DefinedTerm
    106 N40461722296b435f8f29a53a47d5fe99 schema:name Springer Nature - SN SciGraph project
    107 rdf:type schema:Organization
    108 N4b76988fabb44c4e9a63ce96f711fbec schema:issueNumber 5
    109 rdf:type schema:PublicationIssue
    110 N60fe9d1254504a38a7bf9d49322f0614 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Piperazines
    112 rdf:type schema:DefinedTerm
    113 N61de02b4e1494c47a897e3a85e3a0137 schema:name doi
    114 schema:value 10.1038/nm0596-561
    115 rdf:type schema:PropertyValue
    116 N6f046c095cca4813864d9b837c298576 schema:name dimensions_id
    117 schema:value pub.1051513257
    118 rdf:type schema:PropertyValue
    119 N72ecbda58de94354b34b44cd17491bd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Protein-Tyrosine Kinases
    121 rdf:type schema:DefinedTerm
    122 N73480eb3f1e94eb89aaa99ee09a736fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Stem Cells
    124 rdf:type schema:DefinedTerm
    125 N7b9011032abe4b35bfa5951db386ce07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Tumor Cells, Cultured
    127 rdf:type schema:DefinedTerm
    128 N7e16d84c13c54e4797bb52621cb92dc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Blood Cells
    130 rdf:type schema:DefinedTerm
    131 N8309cd70d53b4f36984a66b01364aa26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Animals
    133 rdf:type schema:DefinedTerm
    134 N84d9fc1965a14e97870a2631e61c776e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Evaluation Studies as Topic
    136 rdf:type schema:DefinedTerm
    137 N85997ee65fc64b46b5720141d8b25609 rdf:first sg:person.01111173543.38
    138 rdf:rest Nc9b1cebee4fb46fbbd1953cb43399aa8
    139 N88640ac7e0f349d7be0dcaa5a515b8d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Proto-Oncogene Proteins c-abl
    141 rdf:type schema:DefinedTerm
    142 N8f32df8936524a35a98ee75be95269ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Bone Marrow
    144 rdf:type schema:DefinedTerm
    145 N9c68e041ab674e15967b82bb7a63e446 rdf:first sg:person.07363226302.25
    146 rdf:rest N13f86cdc319440a6b199e1a6f4cfcf43
    147 Na6ba889055cb402eafae6d7e477619f2 rdf:first sg:person.01060303730.59
    148 rdf:rest N00dca75c6e504cc895ef955c9df74fc7
    149 Nb9ebbbbcb2d64c9f8a4c884396129930 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    151 rdf:type schema:DefinedTerm
    152 Nb9f33614dcdb45399a50b0a1d0bd164e schema:name pubmed_id
    153 schema:value 8616716
    154 rdf:type schema:PropertyValue
    155 Nc3a0ba1daaea49338ca4f93d4b5f133c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Mice
    157 rdf:type schema:DefinedTerm
    158 Nc59d1562b22c43d8a533cd6f199aad65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Imatinib Mesylate
    160 rdf:type schema:DefinedTerm
    161 Nc9b1cebee4fb46fbbd1953cb43399aa8 rdf:first sg:person.01123641753.91
    162 rdf:rest N9c68e041ab674e15967b82bb7a63e446
    163 Ne8113372d890432ca4e1c0f8d2443016 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Fusion Proteins, bcr-abl
    165 rdf:type schema:DefinedTerm
    166 Ned74a98405454ca988fbb098a999a6d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Humans
    168 rdf:type schema:DefinedTerm
    169 Nf3dad74e45a5464e8cfbe49d7e534282 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Pyrimidines
    171 rdf:type schema:DefinedTerm
    172 Nfa343c8274514708af289b0f9c0e15d5 schema:volumeNumber 2
    173 rdf:type schema:PublicationVolume
    174 Nfaff3179e4d1441db8898d26b9b173be rdf:first sg:person.0603442270.75
    175 rdf:rest Na6ba889055cb402eafae6d7e477619f2
    176 Nfb95fecde54b47e4b020c08900ebe365 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Enzyme Inhibitors
    178 rdf:type schema:DefinedTerm
    179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    180 schema:name Medical and Health Sciences
    181 rdf:type schema:DefinedTerm
    182 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    183 schema:name Cardiorespiratory Medicine and Haematology
    184 rdf:type schema:DefinedTerm
    185 sg:grant.2410754 http://pending.schema.org/fundedItem sg:pub.10.1038/nm0596-561
    186 rdf:type schema:MonetaryGrant
    187 sg:journal.1113716 schema:issn 1078-8956
    188 1546-170X
    189 schema:name Nature Medicine
    190 schema:publisher Springer Nature
    191 rdf:type schema:Periodical
    192 sg:person.01017774522.42 schema:affiliation grid-institutes:grid.419481.1
    193 schema:familyName Lydon
    194 schema:givenName Nicholas B.
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017774522.42
    196 rdf:type schema:Person
    197 sg:person.01060303730.59 schema:affiliation grid-institutes:grid.419481.1
    198 schema:familyName Buchdunger
    199 schema:givenName Elisabeth
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060303730.59
    201 rdf:type schema:Person
    202 sg:person.01111173543.38 schema:affiliation grid-institutes:grid.5288.7
    203 schema:familyName Segal
    204 schema:givenName Gerald M.
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111173543.38
    206 rdf:type schema:Person
    207 sg:person.01123641753.91 schema:affiliation grid-institutes:grid.5288.7
    208 schema:familyName Fanning
    209 schema:givenName Shane
    210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123641753.91
    211 rdf:type schema:Person
    212 sg:person.012015172137.23 schema:affiliation grid-institutes:grid.5288.7
    213 schema:familyName Druker
    214 schema:givenName Brian J.
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012015172137.23
    216 rdf:type schema:Person
    217 sg:person.0603442270.75 schema:affiliation grid-institutes:grid.5288.7
    218 schema:familyName Tamura
    219 schema:givenName Shu
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603442270.75
    221 rdf:type schema:Person
    222 sg:person.0717670670.09 schema:affiliation grid-institutes:grid.5288.7
    223 schema:familyName Ohno
    224 schema:givenName Sayuri
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717670670.09
    226 rdf:type schema:Person
    227 sg:person.07363226302.25 schema:affiliation grid-institutes:grid.419481.1
    228 schema:familyName Zimmermann
    229 schema:givenName Jürg
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07363226302.25
    231 rdf:type schema:Person
    232 sg:pub.10.1007/bf00124317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011028642
    233 https://doi.org/10.1007/bf00124317
    234 rdf:type schema:CreativeWork
    235 sg:pub.10.1038/243290a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012018569
    236 https://doi.org/10.1038/243290a0
    237 rdf:type schema:CreativeWork
    238 sg:pub.10.1038/306239a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007822085
    239 https://doi.org/10.1038/306239a0
    240 rdf:type schema:CreativeWork
    241 sg:pub.10.1038/306277a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004442914
    242 https://doi.org/10.1038/306277a0
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1038/315550a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045340731
    245 https://doi.org/10.1038/315550a0
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1038/376785a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022545215
    248 https://doi.org/10.1038/376785a0
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1038/bjc.1982.75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008842076
    251 https://doi.org/10.1038/bjc.1982.75
    252 rdf:type schema:CreativeWork
    253 grid-institutes:grid.419481.1 schema:alternateName Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland
    254 schema:name Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland
    255 rdf:type schema:Organization
    256 grid-institutes:grid.5288.7 schema:alternateName Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA
    257 schema:name Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA
    258 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...